The Future of Violence Against Women
By Sujatha Jesudason,
US Women Without Borders
| 02. 21. 2006
Human Rights & the New Genetics
I was born into a culture that embraces confusing messages about the worth and value of women. I grew up in an India where a woman such as Indira Gandhi could become a formidable leader, and yet female infants were routinely killed or starved because they were deemed less valuable than boys. This contradiction played out in my family where smart and competent women who made a difference in the world continued to live with men who abused them, or attempted suicide when their husbands left them. The female role models in my life oscillated between these radical extremes: powerful agents and value-less victims. For as much as I have resisted, this confusion has been a central struggle in my life; I have worked to believe that there is a place for me in this world, that I have a right to enjoyment and happiness, that I matter, and that I have the power to make a difference.
I began working to end violence against women nearly fifteen years ago when I realized that violence is one of the key...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...